MicroRNAs: Novel players in cancer diagnosis and therapies

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Oom, Aaron L ^a   Humphries, Brock A ^a   Yang, Chengfeng ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; MICRORNA; MICRORNA 125B; MICRORNA 200; MICRORNA 21; PROTEIN BCL 2; PROTEIN LET7; PROTEIN TYROSINE KINASE; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERAPY; HUMAN; IRRADIATION; LIPOSOMAL GENE DELIVERY SYSTEM; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; PROTEIN RNA BINDING; PROTEIN TARGETING; REVIEW; VIRAL GENE DELIVERY SYSTEM; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904816107     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/959461     Document Type: Review

References (143)

1. Lee R. C., Feinbaum R. L., Ambros V., The C. elegans heterochronic gene lin -4 encodes small RNAs with antisense complementarity to lin -14. Cell 1993 75 5 843 854 10.1016/0092-8674(93)90529-Y 2-s2.0-0027751663 (Pubitemid 24014542)
2. Chen K., Rajewsky N., The evolution of gene regulation by transcription factors and microRNAs. Nature Reviews Genetics 2007 8 2 93 103 10.1038/nrg1990 2-s2.0-33846283385 (Pubitemid 46122839)
3. Friedman R. C., Farh K. K., Burge C. B., Bartel D. P., Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 2009 19 1 92 105 10.1101/gr.082701.108 2-s2.0-60149095444
4. Kwak P. B., Iwasaki S., Tomari Y., The microRNA pathway and cancer. Cancer Science 2010 101 11 2309 2315 10.1111/j.1349-7006.2010.01683.x 2-s2.0-78049432091
5. Fu X., Tian J., Zhang L., Chen Y., Hao Q., Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Letters 2012 586 9 1279 1286 10.1016/j.febslet.2012.03.006 2-s2.0-84860335557
6. Liang Z., Li Y., Huang K., Wagar N., Shim H., Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharmaceutical Research 2011 28 12 3091 3100 10.1007/s11095-011-0570-y 2-s2.0-83555173262
7. Yang S.-M., Huang C., Li X.-F., Yu M.-Z., He Y., Li J., miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 2013 306 162 168 10.1016/j.tox.2013.02.014 2-s2.0-84876312892
8. Guo P., Nie Q., Lan J., Ge J., Qiu Y., Mao Q., C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochemical and Biophysical Research Communications 2013 441 186 190
9. Li Y., Li L., Guan Y., Liu X., Meng Q., MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochemical and Biophysical Research 2013 440 604 610
10. Zhao G., Cai C., Yang T., Qiu X., Liao B., Li W., Ji Z., Zhao J., Zhao H., Guo M., Ma Q., Xiao C., Fan Q., Ma B., MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS ONE 2013 8 1 e53906 10.1371/journal.pone.0053906 2-s2.0-84872797429
11. Liu Y., Xing R., Zhang X., Dong W., Zhang J., Yan Z., Li W., Cui J., Lu Y., MiR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells. DNA Repair 2013 12 9 741 750 10.1016/j.dnarep.2013.06.002 2-s2.0-84880946591
12. Korpal M., Lee E. S., Hu G., Kang Y., The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. Journal of Biological Chemistry 2008 283 22 14910 14914 10.1074/jbc.C800074200 2-s2.0-47249091921
13. Park S., Gaur A. B., Lengyel E., Peter M. E., The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes and Development 2008 22 7 894 907 10.1101/gad.1640608 2-s2.0-41649091906 (Pubitemid 351482843)
14. Schwarzenbach H., Nishida N., Calin G. A., Pantel K., Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews Clinical Oncology 2014 11 145 156
15. Wang J., Zhang K.-Y., Liu S.-M., Sen S., Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 2014 19 2 1912 1938 10.3390/molecules19021912
16. Yong F. L., Law C. W., Wang C. W., Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 2013 13, article 280 10.1186/1471-2407-13-280 2-s2.0-84878630434
17. Wach S., Nolte E., Szczyrba J., Stöhr R., Hartmann A., Ørntoft T., Dyrskjøt L., Eltze E., Wieland W., Keck B., Ekici A. B., Grässer F., Wullich B., MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. International Journal of Cancer 2012 130 3 611 621 10.1002/ijc.26064 2-s2.0-82255163063
18. Leivonen S.-K., Sahlberg K. K., Mäkelä R., High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Molecular Oncology 2014 8 1 93 104 10.1016/j.molonc.2013.10.001
19. Lemmon M. A., Schlessinger J., Cell signaling by receptor tyrosine kinases. Cell 2010 141 7 1117 1134 10.1016/j.cell.2010.06.011 2-s2.0-77953896432
20. Fasanaro P., D'Alessandra Y., Di Stefano V., Melchionna R., Romani S., Pompilio G., Capogrossi M. C., Martelli F., MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-A3. Journal of Biological Chemistry 2008 283 23 15878 15883 10.1074/jbc.M800731200 2-s2.0-47049119934
21. Oneyama C., Ikeda J., Okuzaki D., Suzuki K., Kanou T., Shintani Y., Morii E., Okumura M., Aozasa K., Okada M., MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 2011 30 32 3489 3501 10.1038/onc.2011.63 2-s2.0-80051791926
22. Acunzo M., Romano G., Palmieri D., Laganá A., Garofalo M., Balatti V., Drusco A., Chiariello M., Nana-Sinkam P., Croce C. M., Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proceedings of the National Academy of Sciences of the United States of America 2013 110 21 8573 8578 10.1073/pnas.1302107110 2-s2.0-84878133983
23. MacKiewicz M., Huppi K., Pitt J. J., Dorsey T. H., Ambs S., Caplen N. J., Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Research and Treatment 2011 130 2 663 679 10.1007/s10549-011-1690-0 2-s2.0-82955248085
24. Feng C., Neumeister V., Ma W., Xu J., Lu L., Bordeaux J., Maihle N. J., Rimm D. L., Huang Y., Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 2012 11 13 2486 2494 10.4161/cc.20893 2-s2.0-84863808561
25. Rao S. A. M., Arimappamagan A., Pandey P., Santosh V., Hegde A. S., Chandramouli B. A., Somasundaram K., miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS ONE 2013 8 5 e63164 10.1371/journal.pone.0063164 2-s2.0-84877858115
26. Kwon J.-E., Kim B.-Y., Kwak S.-Y., Bae I.-H., Han Y.-H., Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis 2013 18 7 896 909 10.1007/s10495-013-0841-7 2-s2.0-84878685848
27. Zhang W., Qian J.-X., Yi H.-L., Yang Z.-D., Wang C.-F., Chen J.-Y., Wei X.-Z., Fu Q., Ma H., The microRNA-29 plays a central role in osteosarcoma pathogenesis and progression. Molecular Biology 2012 46 4 557 562 10.1134/S0026893312040139 2-s2.0-84866457087
28. Ji F., Zhang H., Wang Y., Li M., Xu W., Kang Y., Wang Z., Wang Z., Cheng P., Tong D., Li C., Tang H., MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone 2013 56 1 220 226 10.1016/j.bone.2013.05.020 2-s2.0-84880171505
29. Guo R., Wang Y., Shi W.-Y., Liu B., Hou S.-Q., Liu L., MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. Molecules 2012 17 12 14733 14747 10.3390/molecules171214733 2-s2.0-84871591875
30. Ji Q., Hao X., Zhang M., Tang W., Meng Y., Li L., Xiang D., DeSano J. T., Bommer G. T., Fan D., Fearon E. R., Lawrence T. S., Xu L., MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009 4 8 e6816 10.1371/journal.pone.0006816 2-s2.0-69949087531
31. Zhang H., Li Y., Huang Q., Ren X., Hu H., Sheng H., Lai M., MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death & Differentiation 2011 18 11 1702 1710 10.1038/cdd.2011.28 2-s2.0-80053987030
32. Cimmino A., Calin G. A., Fabbri M., Iorio M. V., Ferracin M., Shimizu M., Wojcik S. E., Aqeilan R. I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C., Kipps T. J., Negrini M., Croce C. M., miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America 2005 102 39 13944 13949 10.1073/pnas.0506654102 2-s2.0-25444520537 (Pubitemid 41377683)
33. Lin C. J., Gong H. Y., Tseng H. C., Wang W. L., Wu J. L., miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochemical and Biophysical Research Communications 2008 375 3 315 320 10.1016/j.bbrc.2008.07.154 2-s2.0-50849115468
34. Downward J., Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer 2003 3 1 11 22 10.1038/nrc969 2-s2.0-0037264633 (Pubitemid 37328883)
35. Kasinski A. L., Slack F. J., MiRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Research 2012 72 21 5576 5587 10.1158/0008-5472.CAN- 12-2001 2-s2.0-84868254278
36. Sun D., Yu F., Ma Y., Zhao R., Chen X., Zhu J., Zhang C., Chen J., Zhang J., MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). The Journal of Biological Chemistry 2013 288 13 9508 9518 10.1074/jbc.M112.367763 2-s2.0-84875994677
37. Shin K.-H., Bae S. D., Hong H. S., Kim R. H., Kang M. K., Park N., miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochemical and Biophysical Research Communications 2011 404 4 896 902 10.1016/j.bbrc.2010.12.055 2-s2.0-79151484006
38. Jang J.-Y., Lee Y.-S., Jeon Y.-K., Lee K., Jang J.-J., Kim C. W., ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma. Experimental and Molecular Medicine 2013 45 1, article e3 10.1038/emm.2013.1 2-s2.0-84876191171
39. Wang R., Wang Z.-X., Yang J.-S., Pan X., De W., Chen L.-B., MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011 30 23 2644 2658 10.1038/onc.2010.642 2-s2.0-79958288052
40. Liu P., Qi M., Ma C., Lao G., Liu Y., Liu Y., Liu Y., Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora-B. FEBS Letters 2013 587 16 2523 2529 10.1016/j.febslet.2013.05.065 2-s2.0-84881481806
41. Shi Z., Zhang J., Qian X., Han L., Zhang K., AC1MMYR2, an inhibitor of dicer-mediated biogenesis of oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res 2013 73 5519 5531
42. Tao T., Wang Y., Luo H., Yao L., Wang L., Wang J., Yan W., Zhang J., Wang H., Shi Y., Yin Y., Jiang T., Kang C., Liu N., You Y., Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. European Journal of Cancer 2013 49 14 3055 3063 10.1016/j.ejca.2013.05.010 2-s2.0-84883055248
43. Tang H., Kong Y., Guo J., Tang Y., Xie X., Yang L., Su Q., Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22. Cancer Letters 2013 340 72 81 10.1016/j.canlet.2013.06.027 2-s2.0-84880335088
44. Fu X., Meng Z., Liang W., Tian Y., Wang X., miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene 2013 10.1038/onc.2013.385
45. Lin Y., Chen H., Hu Z., Mao Y., Xu X., Zhu Y., Xu X., Wu J., Li S., Mao Q., Zheng X., Xie L., MiR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Letters 2013 587 15 2467 2473 10.1016/j.febslet.2013.06.021 2-s2.0-84880699142
46. Banerjee N., Talcott S., Safe S., Mertens-Talcott S. U., Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miRNA-155 in cell survival and inflammation. Breast Cancer Research and Treatment 2012 136 1 21 34 10.1007/s10549-012-2224-0 2-s2.0-84867885344
47. Ye J., Wu X., Wu D., Wu P., Ni C., Zhang Z., Chen Z., Qiu F., Xu J., Huang J., miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS ONE 2013 8 4 e60687 10.1371/journal.pone.0060687 2-s2.0-84876074187
48. Garofalo M., Jeon Y. J., Nuovo G. J., Middleton J., Secchiero P., Joshi P., Alder H., Nazaryan N., Di Leva G., Romano G., Crawford M., Nana-Sinkam P., Croce C. M., MiR-34a/c-dependent PDGFR- α / β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. PLoS ONE 2013 8 6 e67581 10.1371/journal.pone.0067581 2-s2.0-84879267458
49. Liu F., Gong J., Huang W., Wang Z., Wang M., Yang J., Wu C., Wu Z., Han B., MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes. Oncogene 2013 10.1038/onc.2013.428
50. Zhao G., Zhang J.-G., Shi Y., MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS ONE 2013 8 9 e73803 10.1371/journal.pone.0073803
51. Qiu S., Huang D., Yin D., Li F., Li X., Kung H., Peng Y., Suppression of tumorigenicity by MicroRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochimica et Biophysica Acta-Molecular Basis of Disease 2013 1832 10 1697 1707 10.1016/j.bbadis.2013.05.015 2-s2.0-84879567465
52. Wu H., Xiao Z., Wang K., Liu W., Hao Q., MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochemical and Biophysical Research Communications 2013 441 4 693 700 10.1016/j.bbrc.2013.10.053
53. Zhang J.-P., Zeng C., Xu L., Gong J., Fang J.-H., MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling. Oncogene 2013
54. Zhang N., Wei X., Xu L., MiR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Letters 2013 587 15 2346 2351 10.1016/j.febslet.2013.05.059 2-s2.0-84880700831
55. Kong W., He L., Richards E. J., Challa S., Xu C., Permuth-Wey J., Lancaster J. M., Coppola D., Sellers T. A., Djeu J. Y., Cheng J. Q., Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2014 33 679 689 10.1038/onc.2012.636 2-s2.0-84872788613
56. Zhang C., Zhao J., Deng H., 17beta-estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells. Molecular and Cellular Biochemistry 2013 379 1-2 201 211 10.1007/s11010-013- 1642-6 2-s2.0-84878467113
57. Wang Y., Yu Y., Tsuyada A., Ren X., Wu X., Stubblefield K., Rankin-Gee E. K., Wang S. E., Transforming growth factor- Β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011 30 12 1470 1480 10.1038/onc.2010.531 2-s2.0-79953043006
58. Li X., Chen Y. T., Josson S., Mukhopadhyay N. K., Kim J., Freeman M. R., Huang W., MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS ONE 2013 8 8 e70987 10.1371/journal.pone.0070987 2-s2.0-84881241236
59. Kim J.-S., Park S.-Y., Lee S. A., MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. Molecular and Cellular Biochemistry 2014 387 1-2 71 79 10.1007/s11010-013-1872-7
60. kip2 and PUMA. American Journal of Cancer Research 2013 3 465 477
61. Nassirpour R., Mehta P. P., Baxi S. M., Yin M.-J., miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS ONE 2013 8 4 e62170 10.1371/journal.pone.0062170 2-s2.0-84876517143
62. Ma F., Zhang J., Zhong L., Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt / β -catenin signaling. Gene 2014 535 2 191 197 10.1016/j.gene.2013.11.035
63. Martin A., Jones A., Bryar P. J., MicroRNAs-449a and -449b exhibit tumor suppressive effects in retinoblastoma. Biochemical and Biophysical Research 2013 440 599 603
64. Kwak S.-Y., Yang J.-S., Kim B.-Y., Bae I. H., Han Y.-H., Ionizing radiation-inducible miR-494 promotes glioma cell invasion through EGFR stabilization by targeting p190B RhoGAP. Biochimica et Biophysica Acta 2014 1843 3 508 516 10.1016/j.bbamcr.2013.11.021
65. Creevey L., Ryan J., Harvey H., Bray I. M., Meehan M., Khan A. R., Stallings R. L., MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Molecular Cancer 2013 12 1, article 23 10.1186/1476-4598-12-23 2-s2.0-84875318609
66. Song T., Zhang X., Zhang L., Dong J., Cai W., Gao J., Hong B., MiR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. Journal of Cancer Research and Clinical Oncology 2013 139 7 1189 1198 10.1007/s00432-013-1392-6 2-s2.0-84879209019
67. Chen Y., Jacamo R., Konopleva M., Garzon R., Croce C., Andreeff M., CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. Journal of Clinical Investigation 2013 123 6 2395 2407 10.1172/JCI66553 2-s2.0-84878529330
68. Lv K., Liu L., Wang L., Yu J., Liu X., Cheng Y., Dong M., Teng R., Wu L., Fu P., Deng W., Hu W., Teng L., Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS ONE 2012 7 7 e40008 10.1371/journal.pone.0040008 2-s2.0-84863613073
69. Wang L., Yuan C., Lv K., Xie S., Fu P., Liu X., Chen Y., Qin C., Deng W., Hu W., Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and let-7 signaling. PLoS ONE 2013 8 6 e67373 10.1371/journal.pone.0067373 2-s2.0-84879261337
70. Bhutia Y. D., Hung S. W., Krentz M., Patel D., Lovin D., Manoharan R., Thomson J. M., Govindarajan R., Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein. PLoS ONE 2013 8 1 e53436 10.1371/journal.pone. 0053436 2-s2.0-84872412062
71. Guo Y., Yan K., Fang J., Qu Q., Zhou M., Chen F., Let-7b expression determines response to chemotherapy through the regulation of Cyclin D1 in Glioblastoma. Journal of Experimental and Clinical Cancer Research 2013 32 1, article 41 10.1186/1756-9966-32-41 2-s2.0-84879457821
72. Sugimura K., Miyata H., Tanaka K., Hamano R., Takahashi T., Kurokawa Y., Yamasaki M., Nakajima K., Takiguchi S., Mori M., Doki Y., Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clinical Cancer Research 2012 18 18 5144 5153 10.1158/1078-0432.CCR-12-0701 2-s2.0-84866396210
73. Cai J., Yang C., Yang Q., Ding H., Jia J., Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2013 2, article e75
74. Munoz J. L., Bliss S. A., Greco S. J., Ramkissoon S. H., Ligon K. L., Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Molecular Therapy Nucleic Acids 2013 2, article e126
75. Nishida N., Yamashita S., Mimori K., Sudo T., Tanaka F., Shibata K., Yamamoto H., Ishii H., Doki Y., Mori M., MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Annals of Surgical Oncology 2012 19 9 3065 3071 10.1245/s10434-012-2246-1 2-s2.0-84867397137
76. Sun L., Yao Y., Liu B., Lin Z., Lin L., Yang M., Zhang W., Chen W., Pan C., Liu Q., Song E., Li J., MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012 31 4 432 445 10.1038/onc.2011.263 2-s2.0-84856222156
77. Yan H. J., Liu W. S., Sun W. H., Wu J., Ji M., Wang Q., Zheng X., Jiang J., Wu C., MiR-17-5p inhibitor enhances chemosensitivity to gemcitabine via upregulating bim expression in pancreatic cancer cells. Digestive Diseases and Sciences 2012 57 12 3160 3167 10.1007/s10620-012-2400-4 2-s2.0-84871639614
78. Paik W. H., Kim H. R., Park J. K., Song B. J., Lee S. H., Hwang J., Chemosensitivity induced by down-regulation of MicroRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol. Anticancer Research 2013 33 4 1473 1482 2-s2.0-84876768229
79. Hwang J. H., Voortman J., Giovannetti E., Steinberg S. M., Leon L. G., Kim Y. T., Funel N., Park J. K., Kim M. A., Kang G. H., Kim S. W., Del Chiaro M., Peters G. J., Giaccone G., Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 2010 5 5 e10630 10.1371/journal.pone.0010630 2-s2.0-77956296766
80. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J. M., Wang Z., Philip P. A., Sarkar F. H., Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Research 2010 70 9 3606 3617 10.1158/0008-5472.CAN-09-4598 2-s2.0-77951745289
81. Wong S. T. S., Zhang X.-Q., Zhuang J. T.-F., Chan H.-L., Li C.-H., Leung G. K. K., MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Research 2012 32 7 2835 2842 2-s2.0-84865681797
82. Griveau A., Bejaud J., Anthiya S., Avril S., Autret D., Garcion E., Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. International Journal of Pharmaceutics 2013 454 765 774 10.1016/j.ijpharm.2013.05.049 2-s2.0-84879047505
83. Li Y., Li W., Yang Y., Lu Y., He C., Hu G., Liu H., Chen J., He J., Yu H., MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Research 2009 1286 13 18 10.1016/j.brainres.2009. 06.053 2-s2.0-67849103555
84. Gwak H.-S., Kim T. H., Jo G. H., Kim Y.-J., Kwak H., Kim J. H., Yin J., Yoo H., Lee S. H., Park J. B., Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS ONE 2012 7 10 e47449 10.1371/journal.pone.0047449 2-s2.0-84867500470
85. Deng J., Lei W., Fu J.-C., Zhang L., Li J.-H., Xiong J.-P., Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochemical and Biophysical Research Communications 2014 443 3 789 795 10.1016/j.bbrc.2013.11.064
86. Valeri N., Gasparini P., Braconi C., Paone A., Lovat F., Fabbri M., Sumani K. M., Alder H., Amadori D., Patel T., Nuovo G. J., Fishel R., Croce C. M., MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America 2010 107 49 21098 21103 10.1073/pnas.1015541107 2-s2.0-78650500590
87. Elhassan M. O., Christie J., Duxbury M. S., Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistance. Journal of Biological Chemistry 2012 287 8 5267 5277 10.1074/jbc.M111.318865 2-s2.0-84857264871
88. Wang P., Zhang J., Zhang L., MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 2013 145 1133 1143
89. Zhang J., Qian D., Wang F., Liao D., Wei J., Tong Z., Fu J., Huang X., Liao Y., Deng H., Zeng Y., Xie D., Mai S., MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Letters 2013 329 1 91 98 10.1016/j.canlet.2012.10.033 2-s2.0-84871714536
90. Bockhorn J., Dalton R., Nwachukwu C., Huang S., Prat A., Yee K., Chang Y., Huo D., Wen Y., Swanson K. E., Qiu T., Lu J., Park S. Y., Dolan M. E., Perou C. M., Olopade O. I., Clarke M. F., Greene G. L., Liu H., MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature Communications 2013 4, article 1393 10.1038/ncomms2393 2-s2.0-84879177004
91. Su S. F., Chang Y. W., Andreu-Vieyra C., Fang J. Y., Yang Z., Han B., Lee A. S., Liang G., miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene 2012 4694 4701 10.1038/onc.2012.483 2-s2.0-84867593837
92. Mitamura T., Watari H., Wang L., Kanno H., Hassan M. K., Miyazaki M., Katoh Y., Kimura T., Tanino M., Nishihara H., Tanaka S., Sakuragi N., Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2013 2, article e40 10.1038/oncsis.2013.3 2-s2.0-84880554542
93. Li X., Ji M., Zhong S., Zha Q., Xu J., Zhao J., Tang J., MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Archives of Medical Research 2012 43 7 514 521 10.1016/j.arcmed.2012.09. 007 2-s2.0-84869829578
94. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., Deguchi T., Ito M., Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochemical and Biophysical Research Communications 2008 377 1 114 119 10.1016/j.bbrc.2008.09.086 2-s2.0-54449092239
95. Wu H., Huang M., Lu M., Zhu W., Shu Y., Cao P., Liu P., Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemotherapy and Pharmacology 2013 71 5 1159 1171 10.1007/s00280-013-2108-y 2-s2.0-84877926074
96. Huang J.-W., Wang Y., Dhillon K. K., Calses P., Villegas E., Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Molecular Cancer Research 2013 11 12 1564 1573
97. Rao Y., Shi H., Ji M., Chen C., MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. Journal of Huazhong University of Science and Technology 2013 33 4 567 572 10.1007/s11596-013-1160-5 2-s2.0-84881282776
98. Huh J. H., Kim T. H., Kim K., Song J.-., Jung Y. J., Jeong J.-., Lee M. J., Kim Y. K., Lee D. H., An H. J., Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. British Journal of Cancer 2013 109 2 452 461 10.1038/bjc.2013.305 2-s2.0-84881098636
99. Zhou M., Liu Z., Zhao Y., Ding Y., Liu H., Xi Y., Xiong W., Li G., Lu J., Fodstad O., Riker A. I., Tan M., MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. Journal of Biological Chemistry 2010 285 28 21496 21507 10.1074/jbc.M109.083337 2-s2.0-77954378366
100. Liu Z., Liu H., Desai S., Schmitt D. C., Zhou M., Khong H. T., Klos K. S., McClellan S., Fodstad O., Tan M., MiR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. Journal of Biological Chemistry 2013 288 6 4334 4345 10.1074/jbc.M112.419158 2-s2.0-84873638537
101. Wang H., Tan G., Dong L., Cheng L., Li K., Wang Z., Luo H., Circulating mir-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE 2012 7 4 e34210 10.1371/journal.pone.0034210 2-s2.0-84859810024
102. Iida K., Fukushi J., Matsumoto Y., Oda Y., Takahashi Y., Fujiwara T., Fujiwara-Okada Y., Hatano M., Nabashima A., Kamura S., Iwamoto Y., MiR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell International 2013 13 1, article 21 10.1186/1475-2867-13-21 2-s2.0-84874449515
103. Donzelli S., Fontemaggi G., Fazi F., Di Agostino S., Padula F., Biagioni F., Muti P., Strano S., Blandino G., MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death and Differentiation 2012 19 6 1038 1048 10.1038/cdd.2011.190 2-s2.0-84860745157
104. Xu N., Shen C., Luo Y., Xia L., Xue F., Xia Q., Zhang J., Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochemical and Biophysical Research Communications 2012 425 2 468 472 10.1016/j.bbrc.2012.07.127 2-s2.0-84865348811
105. Song B., Wang Y., Xi Y., Kudo K., Bruheim S., Botchkina G. I., Gavin E., Wan Y., Formentini A., Kornmann M., Fodstad O., Ju J., Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009 28 46 4065 4074 10.1038/onc.2009.274 2-s2.0-70450237022
106. van Jaarsveld M. T. M., Helleman J., Boersma A. W. M., van Kuijk P. F., van IJcken W. F., Despierre E., Vergote I., Mathijssen R. H. J., Berns E. M. J. J., Verweij J., Pothof J., Wiemer E. A. C., miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2012 4284 4293 10.1038/onc.2012.433 2-s2.0-84866979755
107. Pagliuca A., Valvo C., Fabrizi E., di Martino S., Biffoni M., Runci D., Forte S., De Maria R., Ricci-Vitiani L., Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 2012 32 4806 4813 10.1038/onc.2012.495 2-s2.0-84868262891
108. Yang Y. P., Chien Y., Chiou G. Y., Cherng J. Y., Wang M., Lo W., Chang Y., Huang P., Chen Y., Shih Y., Chen M., Chiou S., Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012 33 5 1462 1476 10.1016/j.biomaterials.2011.10.071 2-s2.0-83355166283
109. Shi M., Du L., Liu D., Qian L., Hu M., Yu M., Yang Z., Zhao M., Chen C., Guo L., Wang L., Song L., Ma Y., Guo N., Glucocorticoid regulation of a novel HPV-E6-p53- MiR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. Journal of Pathology 2012 228 2 148 157 10.1002/path.3997 2-s2.0-84866248074
110. Xiang Y., Ma N., Wang D., Zhang Y., Zhou J., MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014 33 3 378 386 10.1038/onc.2012.575
111. Cai B., An Y., Lv N., Chen J., Tu M., Sun J., Wu P., Wei J., Jiang K., Miao Y., miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncology Reports 2013 29 5 1769 1776 10.3892/or.2013.2297 2-s2.0-84876255465
112. Takiuchi D., Eguchi H., Nagano H., Iwagami Y., Tomimaru Y., Wada H., Kawamoto K., Kobayashi S., Marubashi S., Tanemura M., Mori M., Doki Y., Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 2013 13 517 523 10.1016/j.pan.2013.06.007 2-s2.0-84879864174
113. Wang J., Sai K., Chen F.-R., Chen Z.-P., miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemotherapy and Pharmacology 2013 72 1 147 158 10.1007/s00280-013-2180-3 2-s2.0-84879796502
114. Wang Y.-Q., Guo R.-D., Sheng W.-M., Yin L.-R., MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. Journal of Cellular Biochemistry 2013 114 7 1464 1473 10.1002/jcb.24488 2-s2.0-84877698814
115. Xu N., Zhang J., Shen C., Luo Y., Xia L., Xue F., Xia Q., Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochemical and Biophysical Research Communications 2012 423 4 826 831 10.1016/j.bbrc.2012.06.048 2-s2.0-84863834241
116. Kopp F., Oak P. S., Wagner E., Roidl A., miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE 2012 7 11 e50469 10.1371/journal.pone.0050469 2-s2.0-84870549360
117. Cochrane D. R., Howe E. N., Spoelstra N. S., Richer J. K., Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. Journal of Oncology 2010 2010 12 821717 10.1155/2010/821717
118. Yang T., Zheng Z.-M., Li X.-N., Li Z.-F., Wang Y., Geng Y. F., Bai L., Zhang X. B., MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Experimental Biology and Medicine 2013 238 9 1024 1032 10.1177/1535370213497321
119. Bao L., Hazari S., Mehra S., Kaushal D., Moroz K., Dash S., Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. American Journal of Pathology 2012 180 6 2490 2503 10.1016/j.ajpath.2012.02.024 2-s2.0-84861591908
120. Liang Z., Ahn J., Guo D., Votaw J. R., Shim H., MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharmaceutical Research 2013 30 4 1008 1016 10.1007/s11095-012-0936-9 2-s2.0-84876491657
121. Hsieh I.-S., Chang K., Tsai Y., Ke J., Lu P., Lee K., Yeh S., Hong T., Chen Y., MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 2013 34 3 530 538 10.1093/carcin/bgs371 2-s2.0-84874782801
122. Iwagami Y., Eguchi H., Nagano H., Akita H., Hama N., Wada H., Kawamoto K., Kobayashi S., Tomokuni A., Tomimaru Y., Mori M., Doki Y., MiR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. British Journal of Cancer 2013 109 2 502 511 10.1038/bjc.2013.320 2-s2.0-84881114885
123. Shen Y., Wang P., Li Y., Ye F., Wang F., Wan X., Cheng X., Lu W., Xie X., MiR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. British Journal of Cancer 2013 109 1 92 99 10.1038/bjc.2013.308 2-s2.0-84880288028
124. Huang J., Cui S., Chen Y., Song H., Huang G., Feng B., Sun M., De W., Wang R., Chen L., MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS ONE 2013 8 8 e72615 10.1371/journal.pone.0072615 2-s2.0-84882602688
125. Hu H., Li S., Cui X., Lv X., Jiao Y., Yu F., Yao H., Song E., Chen Y., Wang M., Lin L., The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). The Journal of Biological Chemistry 2013 288 16 10973 10985 10.1074/jbc.M112.434340 2-s2.0-84876543387
126. Robin T. P., Smith A., McKinsey E., Reaves L., Jedlicka P., Ford H. L., EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Molecular Cancer Research 2012 10 8 1098 1108 10.1158/1541-7786.MCR-12-0086 2-s2.0-84865304256
127. Zhao B., Han H., Chen J., Zhang Z., Li S., Fang F., Zheng Q., MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Letters 2014 342 43 51
128. Soubani O., Ali A. S., Logna F., Ali S., Philip P. A., Sarkar F. H., Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 2012 33 8 1563 1571 10.1093/carcin/bgs189 2-s2.0-84865328547
129. Prislei S., Martinelli E., Mariani M., Raspaglio G., Sieber S., Ferrandina G., Shahabi S., Scambia G., Ferlini C., MiR-200c and HuR in ovarian cancer. BMC Cancer 2013 13, article 72 10.1186/1471-2407-13-72 2-s2.0-84873422357
130. Hur K., Toiyama Y., Takahashi M., Balaguer F., Nagasaka T., Koike J., Hemmi H., Koi M., Boland C. R., Goel A., MicroRNA-200c modulates epithelial-tomesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013 62 9 1315 1326 10.1136/gutjnl-2011-301846 2-s2.0-84881551103
131. Guo Z., Zhou B., Liu W., Xu Y., Wu D., Yin Z., Permatasari F., Luo D., MiR-23a regulates DNA damage repair and apoptosis in UVB-irradiated HaCaT cells. Journal of Dermatological Science 2013 69 1 68 76 10.1016/j.jdermsci.2012.10. 014 2-s2.0-84870918541
132. Tan G., Niu J., Shi Y., Ouyang H., Wu Z., NF- B-dependent MicroRNA-125b up-regulation promotes cell survival by targeting p38 α upon ultraviolet radiation. Journal of Biological Chemistry 2012 287 39 33036 33047 10.1074/jbc.M112.383273 2-s2.0-84866550126
133. Mueller A. C., Sun D., Dutta A., The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene 2013 32 9 1164 1172 10.1038/onc.2012.131 2-s2.0-84874668158
134. Ando H., Okamoto A., Yokota M., Polycation liposomes as a vector for potential intracellular delivery of microRNA. The Journal of Gene Medicine 2013 15 375 383 10.1002/jgm.2744
135. Biray A., Özcan I., Balci T., Özer Ö., Gündüz C., Design of polyethylene glycol- polyethylenimine nanocomplexes as non-viral carriers: miR-150 delivery to chronic myeloid leukemia cells. Cell Biology International 2013 37 1205 1214
136. Cao M., Deng X., Su S., Zhang F., Xiao X., Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells. Nanoscale 2013 5 12120 12125
137. Lv H., Zhang S., Wang B., Cui S., Yan J., Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of Controlled Release 2006 114 1 100 109 10.1016/j.jconrel.2006.04.014 2-s2.0-33746438424 (Pubitemid 44128621)
138. Shi S. J., Zhong Z. R., Liu J., Zhang Z. R., Sun X., Gong T., Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharmaceutical Research 2012 29 1 97 109 10.1007/s11095-011-0514-6 2-s2.0-84859016052
139. Trang P., Wiggins J. F., Daige C. L., Cho C., Omotola M., Brown D., Weidhaas J. B., Bader A. G., Slack F. J., Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Molecular Therapy 2011 19 6 1116 1122 10.1038/mt.2011.48 2-s2.0-79957900919
140. Piao L., Zhang M., Datta J., Xie X., Su T., Li H., Teknos T. N., Pan Q., Lipid-based nanoparticle delivery of pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Molecular Therapy 2012 20 6 1261 1269 10.1038/mt.2012.67 2-s2.0-84861902017
141. Zhu X., Lv M., Wang H., Guan W., Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. Digestive Diseases and Sciences 2014 59 5 911 919 10.1007/s10620-013-2970-9
142. Grimm D., Streetz K. L., Jopling C. L., Storm T. A., Pandey K., Davis C. R., Marion P., Salazar F., Kay M. A., Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006 441 7092 537 541 10.1038/nature04791 2-s2.0-33745299723 (Pubitemid 44050158)
143. Liu X.-Y., Tang Q.-S., Chen H.-C., Jiang X.-L., Fang H., Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. International Journal of Biological Sciences 2013 9 6 564 577 10.7150/ijbs.5425 2-s2.0-84879322199